Pomalidomide (Pomalyst) for multiple myeloma.
出版信息
Med Lett Drugs Ther. 2015 Apr 27;57(1467):e66-7.
PMID:25988965
Abstract
摘要
相似文献
1
Pomalidomide (Pomalyst) for multiple myeloma.
Med Lett Drugs Ther. 2015 Apr 27;57(1467):e66-7.
2
Impact of pomalidomide therapy in multiple myeloma: a recent survey.
J Chemother. 2014 Dec;26(6):321-7. doi: 10.1179/1973947814Y.0000000201. Epub 2014 Jul 9.
3
[Pomalidomide for multiple myeloma].
Bull Cancer. 2017 Sep;104(9):707-713. doi: 10.1016/j.bulcan.2017.04.005. Epub 2017 Jun 2.
4
Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Expert Rev Anticancer Ther. 2014 May;14(5):499-510. doi: 10.1586/14737140.2014.906904. Epub 2014 Apr 17.
5
Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
Am J Hematol. 2010 Feb;85(2):95-6. doi: 10.1002/ajh.21610.
6
Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Crit Rev Oncol Hematol. 2013 Oct;88 Suppl 1:S36-44. doi: 10.1016/j.critrevonc.2013.02.001. Epub 2013 Jun 17.
7
Pomalidomide.
Blood. 2013 Oct 3;122(14):2305-9. doi: 10.1182/blood-2013-05-484782. Epub 2013 Aug 23.
8
Pomalidomide: when expectations are understated.
Future Oncol. 2017 Feb;13(5s):1-2. doi: 10.2217/fon-2016-0559.
9
The safety of pomalidomide for the treatment of multiple myeloma.
Expert Opin Drug Saf. 2016;15(4):535-47. doi: 10.1517/14740338.2016.1154039. Epub 2016 Mar 16.
10
Thalidomide and lenalidomide in multiple myeloma.
Best Pract Res Clin Haematol. 2006;19(4):769-80. doi: 10.1016/j.beha.2006.06.006.
Zotero 插件